Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients withAcquired Hypothalamic Obesity
Company to host conference call on April 7 at 8 a.m. ET…
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimers Disease
ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified…
The Second Phase of the Selection Process of ICFAI Business School Scheduled for April 5-6: Today is the Last Day to Apply for 8 Campuses
HYDERABAD, India, April 3, 2025 /PRNewswire/ -- The second phase of the…
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Target enrollment exceeded with 1009 patients randomized in the main cohort and 410…
Bounteous Names Sudarshan Mandayam as CEO to Lead Next Phase of Digital Innovation and Growth
CHICAGO, March 26, 2025 /PRNewswire/ -- Bounteous, a leading global digital transformation consultancy,…
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint
Demonstrated substantial and statistically significant improvement in ADHD symptoms as measured by…
Fractal Invests $20 Million in Asper.AI to Drive Next Phase of Growth and Innovation
NEW YORK and MUMBAI, India , March 19, 2025 /PRNewswire/ -- Fractal (www.fractal.ai), a…
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial
Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470…
Lungpacer Medical Announces Investigational Device Exemption (IDE) for STARI, Phase 2 Feasibility Clinical Trial
The investigational AeroNova® System delivers continual diaphragm neurostimulation in conjunction with mechanical…
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor…